<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35094639</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">2150-5608</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Virulence</Title>
          <ISOAbbreviation>Virulence</ISOAbbreviation>
        </Journal>
        <ArticleTitle><i>Pseudomonas aeruginosa</i> adaptation in cystic fibrosis patients increases C5a levels and promotes neutrophil recruitment.</ArticleTitle>
        <Pagination>
          <StartPage>215</StartPage>
          <EndPage>224</EndPage>
          <MedlinePgn>215-224</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/21505594.2022.2028484</ELocationID>
        <Abstract>
          <AbstractText>Cystic fibrosis (CF) disease is characterized by an intense airway inflammatory response mediated by neutrophils and chronic respiratory infections caused by <i>P. aeruginosa</i>. High levels of the complement component C5a, the strongest neutrophil chemoattractant molecule, are commonly found in the CF lung and have been associated with a worsening of the disease. In this study, we investigated how the isolates from CF patients modulate the levels of C5a and identified the bacterial factors involved. We demonstrated that most isolates from airway chronic infections induce the production and accumulation of C5a, an effect attributable to the loss of C5a cleavage by the exoproteases alkaline protease (AprA) and elastase B (LasB). Furthermore, we found that lack of the bacterial protease-dependent C5a degradation is due to mutations in the master regulator LasR. Thus, complementation of a non-C5a-cleaving CF isolate with a functional wild-type LasR restored its ability to express both proteases, cleave C5a and reduce neutrophil recruitment in vitro. These findings suggest that the non-cleaving C5a phenotype acquired by the LasR variants frequently isolated in CF patients may account for the strong neutrophilia and general neutrophil dysfunction predisposing toward increased inflammation and reduced bacterial clearance described in CF patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mateu-Borrás</LastName>
            <ForeName>Margalida</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de Investigación En Ciencias de La Salud, Universidad de Las Islas Baleares and Instituto de Investigación Sanitaria de Les Illes Balears, Palma de Mallorca, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>González-Alsina</LastName>
            <ForeName>Alex</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de Investigación En Ciencias de La Salud, Universidad de Las Islas Baleares and Instituto de Investigación Sanitaria de Les Illes Balears, Palma de Mallorca, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Doménech-Sánchez</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de Investigación En Ciencias de La Salud, Universidad de Las Islas Baleares and Instituto de Investigación Sanitaria de Les Illes Balears, Palma de Mallorca, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Querol-García</LastName>
            <ForeName>Javier</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fernández</LastName>
            <ForeName>Francisco J</ForeName>
            <Initials>FJ</Initials>
            <AffiliationInfo>
              <Affiliation>Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vega</LastName>
            <ForeName>Mª Cristina</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas, Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Albertí</LastName>
            <ForeName>Sebastián</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto Universitario de Investigación En Ciencias de La Salud, Universidad de Las Islas Baleares and Instituto de Investigación Sanitaria de Les Illes Balears, Palma de Mallorca, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Virulence</MedlineTA>
        <NlmUniqueID>101531386</NlmUniqueID>
        <ISSNLinking>2150-5594</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>80295-54-1</RegistryNumber>
          <NameOfSubstance UI="D015936">Complement C5a</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.-</RegistryNumber>
          <NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015936" MajorTopicYN="N">Complement C5a</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003550" MajorTopicYN="Y">Cystic Fibrosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020556" MajorTopicYN="N">Neutrophil Infiltration</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011552" MajorTopicYN="Y">Pseudomonas Infections</DescriptorName>
          <QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011550" MajorTopicYN="N">Pseudomonas aeruginosa</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012137" MajorTopicYN="N">Respiratory System</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">C5a</Keyword>
        <Keyword MajorTopicYN="Y">alkaline protease A</Keyword>
        <Keyword MajorTopicYN="Y">cystic fibrosis</Keyword>
        <Keyword MajorTopicYN="Y">elastase B</Keyword>
        <Keyword MajorTopicYN="Y">lasR</Keyword>
      </KeywordList>
      <CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35094639</ArticleId>
        <ArticleId IdType="pmc">PMC8802900</ArticleId>
        <ArticleId IdType="doi">10.1080/21505594.2022.2028484</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lyczak JB, Cannon CL, Pier GB.. 
Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15(2):194–222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC118069</ArticleId>
            <ArticleId IdType="pubmed">11932230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Winstanley C, O’Brien S, Brockhurst MA. Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol. 2016;24(5):327–337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4854172</ArticleId>
            <ArticleId IdType="pubmed">26946977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marvig RL, Sommer LM, Molin S, et al. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat Genet. 2015;47(1):57–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25401299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen D, Singh PK. Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections. Proc Natl Acad Sci USA. 2006;103(22):8305–8306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1482488</ArticleId>
            <ArticleId IdType="pubmed">16717189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11(9):785–797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2924908</ArticleId>
            <ArticleId IdType="pubmed">20720586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol. 2004;4(2):133–142.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15040586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conway Morris A, Kefala K, Wilkinson, TS, et al. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. Am J Respir Crit Care Med. 2009;180(1):19–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2948533</ArticleId>
            <ArticleId IdType="pubmed">19324972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wood AJ, Vassallo AM, Ruchaud-Sparagano MH, et al. C5a impairs phagosomal maturation in the neutrophil through phosphoproteomic remodeling. J Clin Invest Insight. 2020;5. e137029.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7455072</ArticleId>
            <ArticleId IdType="pubmed">32634128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sass LA, Hair PS, Perkins AM, et al. Complement effectors of inflammation in cystic fibrosis lung fluid correlate with clinical measures of disease. PLoS ONE. 2015;10(12):e0144723.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4671727</ArticleId>
            <ArticleId IdType="pubmed">26642048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>RB F Jr, Robbins RA, Squier SU, et al. Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res. 1986;20(12):1258–1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3540828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hair PS, Sass LA, Vazifedan T, et al. Complement effectors, C5a and C3a, in cystic fibrosis lung fluid correlate with disease severity. PLoS One. 2017;12(3):e0173257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5344399</ArticleId>
            <ArticleId IdType="pubmed">28278205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López-Causapé C, Rojo-Molinero E, Cabot G, et al. Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. PLoS One. 2013;8(8):e71001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3741393</ArticleId>
            <ArticleId IdType="pubmed">23951065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbier M, Oliver A, Rao J, et al. Novel phosphorylcholine-containing protein of Pseudomonas aeruginosa chronic infection isolates interacts with airway epithelial cells. J Infect Dis. 2008;197(3):465–473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18184091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casilag F, Lorenz A, Krueger J, et al. The LasB elastase of Pseudomonas aeruginosa acts in concert with alkaline protease AprA to prevent flagellin-mediated immune recognition. Infect Immun. 2015;84(1):162–171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4693985</ArticleId>
            <ArticleId IdType="pubmed">26502908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kirchner S, Fothergill JL, Wright EA, et al. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. J Vis Exp. 2012; (64):e3857. DOI:10.3791/3857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3791/3857</ArticleId>
            <ArticleId IdType="pmc">PMC3471314</ArticleId>
            <ArticleId IdType="pubmed">22711026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watford WT, Ghio JA, Wright JR. Complement-mediated host defense in the lung. Am J Physiol Lung Cell Mol Physiol. 2000;279(5):790–798.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11053012</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11846609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Owings JP, Kuiper EG, Prezioso SM, et al. Pseudomonas aeruginosa EftM Is a thermoregulated methyltransferase. J Biol Chem. 2016;291(7):3280–3290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4751374</ArticleId>
            <ArticleId IdType="pubmed">26677219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor NY: Cold Spring Harbor Laboratory Press; 1989.</Citation>
        </Reference>
        <Reference>
          <Citation>Mosca T, Forte WC. Comparative efficiency and impact on the activity of blood neutrophils isolated by Percoll, Ficoll and spontaneous sedimentation methods. Immunol Invest. 2016;45(1):29–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26699845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laarman AJ, Bardoel BW, Fernie J, et al. Pseudomonas aeruginosa alkaline protease blocks complement activation via the classical and lectin pathways. J Immunol. 2012;188(1):386–393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22131330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hong YQ, Ghebrehiwet B. Effect of Pseudomonas aeruginosa elastase and alkaline protease on serum complement and isolated components C1q and C3. Clin Immunol Immunopathol. 1992;62(2):133–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1730152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerquetti MC, Sordelli DO, Bellanti JA, et al. Lung defenses against Pseudomonas aeruginosa in C5-deficient mice with different genetic backgrounds. Infect Immun. 1986;52(3):853–857.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC260938</ArticleId>
            <ArticleId IdType="pubmed">3086235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hopken UE, Lu B, Gerard NP, et al. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature. 1996;383(6595):86–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8779720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vitkauskiene A, Scheuss S, Sakalauskas R, et al. Pseudomonas aeruginosa strains from nosocomial pneumonia are more serum resistant than P. aeruginosa strains from noninfectious respiratory colonization processes. Infection. 2005;33(5–6):356–361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16258867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wexler DE, Chenoweth DE, Cleary PP. Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci U S A. 1985;82(23):8144–8148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC391459</ArticleId>
            <ArticleId IdType="pubmed">3906656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi S, Nagano Y, Nagano N, et al. Role of C5a-ase in group B streptococcal resistance to opsonophagocytic killing. Infect Immun. 1995;63(12):4764–4769.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC173682</ArticleId>
            <ArticleId IdType="pubmed">7591133</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantin AM, Hartl D, Konstan MW, et al. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros. 2015;14(4):419–430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25814049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith EE, Buckley DG, Wu Z, et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A. 2006;103(22):8487–8492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1482519</ArticleId>
            <ArticleId IdType="pubmed">16687478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Argenio DA, Wu M, Hoffman LR, et al. Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol Microbiol. 2007;64(2):512–533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2742308</ArticleId>
            <ArticleId IdType="pubmed">17493132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman LR, Kulasekara HD, Emerson J, et al. Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression. J Cyst Fibros. 2009;8(1):66–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2631641</ArticleId>
            <ArticleId IdType="pubmed">18974024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feltner JB, Wolter DJ, Pope CE, et al. LasR variant cystic fibrosis isolates reveal an adaptable quorum-sensing hierarchy in Pseudomonas aeruginosa. mBio. 2016;7(5):e01513–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5050340</ArticleId>
            <ArticleId IdType="pubmed">27703072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>LaFayette SL, Houle D, Beaudoin T, et al. Cystic fibrosis–adapted Pseudomonas aeruginosa quorum sensing lasR mutants cause hyperinflammatory responses. Sci Adv. 2015;1(6):e1500199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4597794</ArticleId>
            <ArticleId IdType="pubmed">26457326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hennemann LC, LaFayette SL, Malet JK, et al. LasR-deficient Pseudomonas aeruginosa variants increase airway epithelial mICAM-1 expression and enhance neutrophilic lung inflammation. PLoS Pathog. 2021;17(3):e1009375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7984618</ArticleId>
            <ArticleId IdType="pubmed">33690714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alexis NE, Muhlebach MS, Peden DB, et al. Attenuation of host defense function of lung phagocytes in young cystic fibrosis patients. J Cyst Fibros. 2006;5(1):17–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1764441</ArticleId>
            <ArticleId IdType="pubmed">16356787</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
